The manufacturer, Lilly, recommends rotating the location of the dose to prevent skin irritation
placebo ranged from -8.8% (95% CI -10.3, -6.3) to -6.9% (95% CI -9.1, -4.7) from no diuretics to the highest loop diuretic dose category
What We Know So Far The clinical trials that established the safety and efficacy of GLP-1 medications, including the STEP and SURMOUNT trial programs for semaglutide and tirzepatide, respectively, enrolled predominantly middle-aged adults
It is also worth noting that both medications can affect the central nervous system, and their combined use may lead to unpredictable outcomes, especially in those with compromised health or those taking multiple medications
CARDIOVASCULAR RISK These findings clearly made it attractive to exploit the GLP-1 hormone for diabetes therapy and, indeed, a continuous subcutaneous infusion of GLP-1 over six weeks produced marked reductions of glycated haemoglobin and improvements in beta cell function along with weight loss in people with advanced T2DM [12]
Improving insulin sensitivity can also help manage high blood pressure, reducing the risk of heart disease
